Brian Bergmark, MD
Cardiovascular Disease · Boston, MANPI 1750676375
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $205,375 of the $290,885 with a category attached, or 70.6%. 16 manufacturers reported payments, led by Abbott at 54.7% of the total. 2025 is the largest year on record at $97,095, 4.3 times the $22,724 reported in 2019. Among cardiovascular disease clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 308 payments — averaging $944.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$159K
- Shockwave Medical, Inc$62K
- Teleflex LLC$21K
- Abiomed$18K
- Boston Scientific$18K
- Spectrawave, Inc$5K
- plus $8K from 10 others
Across 147 payments — averaging $54,264 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$7.6M
- Abbott$135K
- Spectrawave, Inc$102K
- Pfizer$63K
- Cardiovascular Systems Inc.$54K
- Inari Medical, Inc.$39K
- plus $11K from 1 others
What the payments were for
- Consulting fees$205,37571%
- Speaking & faculty fees$57,59020%
- Travel & lodging$15,6355%
- Food & beverage$12,0934%
- Education$1920%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 153 | $159,060 |
| Shockwave Medical, Inc | 48 | $61,969 |
| Teleflex LLC | 18 | $20,948 |
| Abiomed | 19 | $18,108 |
| Boston Scientific | 20 | $18,045 |
| Spectrawave, Inc | 6 | $4,500 |
| Magenta Medical Inc | 3 | $4,107 |
| Cardiovascular Systems Inc. | 14 | $2,672 |
| Terumo Medical Corporation | 2 | $700 |
| Philips North America LLC | 11 | $507 |
| Amgen | 6 | $121 |
| Inari Medical, Inc. | 3 | $59 |
| Stryker | 2 | $39 |
| Heartflow, Inc. | 1 | $23 |
| Pfizer | 1 | $16 |
| Astrazeneca UK Limited | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OPTIS$107,094
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$61,309
- Xience V coronary stent system$29,623
- Impella$18,008
- HI-TORQUE BALANCE$13,250
- GUIDELINER V3 CATHETER$9,900
- TURNPIKE$9,725
- Vitalyst$5,173
- HyperVue Imaging System$4,500
- Starlight Imaging Catheter$4,000
- GENERAL VASCULAR ACCESS$2,500
- Diamondback Coronary$2,171
- Dragonfly OCT$1,500
- Ultreon$1,500
- GUIDELINER$960
- SUPERA$711
- Optis Coronary Imaging System$554
- XIENCE SIERRA$447
- Optitorque$350
- Peripheral Orbital Atherectomy System$314
How this compares
$290,885 in reported general payments places this provider in the 95th percentile of 750 cardiovascular disease providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ranolazine ErRanolazine | 18 | $3,201 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 17 | $923 |
| Metoprolol Succinate | 25 | $889 |
| Rosuvastatin Calcium | 21 | $778 |
| Ezetimibe | 18 | $684 |
| Atorvastatin Calcium | 22 | $388 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Boston
- Marc SabatineBoston$3.9M
- Elizabeth NabelBoston$2.2M
- Kenneth RosenfieldBoston$1.4M
- James JanuzziBoston$1.1M
- Muthiah VaduganathanBoston$972K
- Joseph LoscalzoBoston$926K
- Sunil KapurBoston$823K
- Paul ZeiBoston$786K
- Paul RidkerBoston$572K
- Ignacio Inglessis-AzuajeBoston$545K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.